New Australian Collaboration Launches an IBM Pilot Trial — and a Way to Spot Progress Far Earlier
Every IBM patient knows the brutal math of clinical trials: the disease moves slowly, strength tests are blunt instruments, and a therapy can look ineffective for years before anyone can tell whether it is actually helping. A new Australian collaboration is attacking that exact problem.
What the Collaboration Is Doing
The Snow Centre for Immune Health, together with WEHI (the Walter and Eliza Hall Institute of Medical Research) and the Royal Melbourne Hospital, has launched a pilot clinical trial testing a therapy that targets immune pathways believed to drive IBM. The work is led by Dr Jessica Day, a rheumatologist at the Royal Melbourne Hospital and Senior Research Officer at WEHI.
The trial is the first step of a broader project: to identify biomarkers — measurable biological signals that can be tracked in blood or tissue — that serve as early indicators of whether a treatment is working.
Why Biomarkers Matter So Much
Today, no treatment can slow or stop IBM. One major reason progress has been slow is that clinical trials in IBM rely on slow-changing measures like muscle strength and mobility. Because the disease progresses gradually, it can take a long time to detect even a real treatment effect — which means promising therapies can be written off, and the wait for answers stretches on.
The team's goal is to build a research platform that can reveal whether a therapy is working much earlier than existing methods. "It gives us a faster, more accurate way to understand whether a treatment is having an effect — something that could transform the search for real therapies," Dr Day said.
For the first time, the Snow Centre — a partnership built around improving immune health — has invited clinician-scientists from partner organizations to codesign research projects. Snow Centre Director Professor Jason Tye-Din put the stakes plainly: "People living with IBM have waited far too long for progress. This project could speed up the development of the first-ever effective treatment for IBM."
What This Means for IBM Patients
This is early-stage news: the specific therapy, the study design, and eligibility details have not yet been released, and pilot trials are small by design. What matters is the strategy behind it. Instead of just testing another drug against a slow-moving disease, this project is building the measurement tools that make all future IBM trials faster and smarter.
If it works, it could shorten the time to answers in every IBM trial that follows — and give the community something it has never had: a way to see, months earlier, whether a treatment is on the right track.
The team says updates will be shared through the Myositis Australia website, the Snow Centre website, and its newsletter, and people interested in the study can register their interest with the research team.
Source
• WEHI News, "New research offers hope to people living with a life-altering muscle condition." May 26, 2026. wehi.edu.au
• Snow Centre for Immune Health, "Inclusion body myositis study." snowimmunehealth.org.au
Tags
Related Reading
- Early Stage Tips — Exercise, energy conservation, and specialist directories
- Bathroom & Toileting — Equipment, bidets, and transfer techniques
- Travel Tips — Airlines, hotels, and emergency preparedness
- General Tips — Insurance, disability benefits, and support groups